chr3-48575419-C-T
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000094.4(COL7A1):c.6100G>A(p.Gly2034Arg) variant causes a missense change. The variant allele was found at a frequency of 0.000000686 in 1,457,728 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G2034A) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000094.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
COL7A1 | NM_000094.4 | c.6100G>A | p.Gly2034Arg | missense_variant | 74/119 | ENST00000681320.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
COL7A1 | ENST00000681320.1 | c.6100G>A | p.Gly2034Arg | missense_variant | 74/119 | NM_000094.4 | P1 | ||
COL7A1 | ENST00000328333.12 | c.6100G>A | p.Gly2034Arg | missense_variant | 73/118 | 1 | P1 | ||
COL7A1 | ENST00000487017.5 | n.2017G>A | non_coding_transcript_exon_variant | 39/83 | 5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000418 AC: 1AN: 238994Hom.: 0 AF XY: 0.00000763 AC XY: 1AN XY: 131068
GnomAD4 exome AF: 6.86e-7 AC: 1AN: 1457728Hom.: 0 Cov.: 39 AF XY: 0.00000138 AC XY: 1AN XY: 725106
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 16, 2023 | One of the most common pathogenic variants in individuals with autosomal dominant dystrophic epidermolysis bullosa (DDEB); G2034R and G2043R account for up 50% of the DDEB pathogenic variants reported in the largest US cohort (Varki et al., 2007; Pfendner and Lucky, 2018); Located in the highly conserved Gly-X-Y repeat of the collagenous domain; Glycine substitution variants in this region of the COLVII protein destabilize the collagen triple helix resulting in skin fragility due to poor anchoring of the basement membrane to the underlying dermis (Pfendner and Lucky, 2018); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25113066, 21448560, 11874498, 10084325, 9856844, 2653224, 9215684, 31001817, 34046686, 32484238, 11218887, 33274474, 9347800, 16971478, 34543471) - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 11, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 2034 of the COL7A1 protein (p.Gly2034Arg). This variant is present in population databases (rs121912844, gnomAD 0.003%). This missense change has been observed in individual(s) with autosomal dominant epidermolysis bullosa dystrophica (PMID: 9347800). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 17450). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL7A1 protein function with a positive predictive value of 95%. This variant disrupts the triple helix domain of COL7A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL7A1 are more frequently observed in individuals with disease than in the general population (PMID: 22058051). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. For these reasons, this variant has been classified as Pathogenic. - |
Generalized dominant dystrophic epidermolysis bullosa Pathogenic:1Other:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2002 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Epidermolysis bullosa dystrophica Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Biomedical Innovation Departament, CIEMAT | Dec 02, 2019 | - - |
COL7A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 19, 2024 | The COL7A1 c.6100G>A variant is predicted to result in the amino acid substitution p.Gly2034Arg. This variant has been reported in many individuals with dystrophic epidermolysis bullosa (see for example, Kon et al. 1997. PubMed ID: 9347800; Mariath et al. 2019. PubMed ID: 31001817; Chen et al. 2020. PubMed ID: 32484238). This variant resides in exon 73 and results in a glycine amino acid substitution. Glycine substitution variants in the triple helical domain (Gly-X-Y; especially in exons 73, 74, and 75) are predominant in autosomal dominant dystrophic epidermolysis bullosa (DDEB; https://www.ncbi.nlm.nih.gov/books/NBK1304/). This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
Recessive dystrophic epidermolysis bullosa;C0432322:Generalized dominant dystrophic epidermolysis bullosa Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Feb 17, 2022 | ACMG classification criteria: PS4 strong, PM1 moderate, PM2 moderate, PP1 strong, PP3 supporting - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at